Meet the Tiny Biotech Challenging Amgen and General Electric
Repligen only has one product in manufacturing equipment, but it may be a better way to capitalize on the growing trend in biotech manufacturing than Amgen and General Electric.
3 Future Stars in Big Pharma's Best Pipeline
Johnson & Johnson is no stranger to developing strong pharmaceuticals for the long term, but which drugs should you keep an eye on that will keep this company's business on track in the future?
A Closer Look at Pfizer's Oncology Business
Will Pfizer’s oncology business finally help the company grow its top line again?
AstraZeneca's Turnaround Story Hasn't Started Yet
Did Q3 mark the beginning of a comeback for AstraZeneca? Not hardly. Investors might have to wait quite a while to hear this turnaround story.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Eli Lilly, Amgen, and Merck KGaA all face big hits at the end of 2013 as generic competition revs for these three billion-dollar drugs.